Showing all 6 results
Erlotinib Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical stability of the targeted antineoplastic API.
Active Ingredient Strength Primary Clinical Function Erlotinib (as Hydrochloride) USP/Ph.Eur. 100 mg The Pancreatic Oncology Standard: The definitive daily maintenance dose utilized globally in combination with Gemcitabine for advanced, unresectable, or metastatic pancreatic cancer. Erlotinib (as Hydrochloride) USP/Ph.Eur. 150 mg The Thoracic Oncology Standard: Massive therapeutic payload utilized as a first-line, maintenance, or second-line daily monotherapy for EGFR-mutated Non-Small Cell Lung Cancer. Excipients Lactose Monohydrate / Microcrystalline Cellulose / Sodium Starch Glycolate / Sodium Lauryl Sulfate / Magnesium Stearate / Premium Polymeric Film Diluent / Binder / Superdisintegrant / Surfactant / Heavy Film-Coating (Engineered specifically to maximize dissolution of this highly insoluble compound while locking the potent cytotoxic API safely inside the tablet, completely preventing handler exposure to carcinogenic dust) *Pack Sizes: 3×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic oncology dispensing regimens).
Gefitinib tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical stability of the targeted antineoplastic agent.
Active Ingredient Strength Primary Clinical Function Gefitinib USP/Ph.Eur. 250 mg Global Adult Oncology Standard: The definitive, highly precise daily maintenance dose required to maintain constant, paralyzing pressure on the mutated EGFR protein to keep the lung cancer in deep molecular remission. Excipients Lactose Monohydrate / Microcrystalline Cellulose / Croscarmellose Sodium / Sodium Lauryl Sulfate / Magnesium Stearate / Premium Polymeric Film Diluent / Binder / Superdisintegrant / Surfactant / Heavy Film-Coating (Engineered specifically to maximize the dissolution of this poorly soluble compound while locking the cytotoxic API safely inside the tablet, completely preventing handler and pharmacist exposure to the carcinogenic dust) *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic oncology dispensing regimens).
Imatinib Capsules
FreeImatinib capsules contain the active oncology drug and a specific set of inactive ingredients designed to stabilize the compound for oral delivery.
Imatinib tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical stability of the mesylate salt.
Active Ingredient Strength Primary Clinical Function Imatinib (as Mesylate) USP/Ph.Eur. 100 mg Pediatric & Titration Standard: Base therapeutic unit utilized for weight-based pediatric leukemia dosing, or for highly precise adult dose adjustments during acute hematological toxicity. Imatinib (as Mesylate) USP/Ph.Eur. 400 mg Global Adult Oncology Standard: High-efficacy adult maintenance dose, typically taken once daily for the chronic phase of CML, or twice daily for accelerated phases and GIST. Excipients Microcrystalline Cellulose / Crospovidone / Hypromellose / Colloidal Silicon Dioxide / Magnesium Stearate / Premium Iron-Oxide Film Diluent / Superdisintegrant / Binder / Glidant / Heavy Film-Coating (Engineered specifically to lock the cytotoxic API safely inside the tablet, completely preventing handler and pharmacist exposure to the carcinogenic dust) *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic oncology dispensing regimens).
Sorafenib tablets 200mg
FreeA Sorafenib 200mg tablet is an oral multi-kinase inhibitor primarily containing Sorafenib as the active substance. It is used as a targeted therapy to treat advanced kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma), and certain types of thyroid cancer.
